Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
115.61
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Mar 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,234
Open
115.61
Bid (Size)
114.95 (300)
Ask (Size)
116.00 (200)
Prev. Close
115.61
Today's Range
115.61 - 115.61
52wk Range
73.31 - 125.14
Shares Outstanding
2,531,374,696
Dividend Yield
2.94%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
1 ETF That Could Turn $100 Per Month Into $67,380
↗
March 15, 2026
How does solid growth -- plus a 3.3% dividend yield sound?
Via
The Motley Fool
Topics
ETFs
Economy
World Trade
Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm
March 13, 2026
In a day marked by heightened global tensions and a sharp spike in energy prices, the U.S. equity markets witnessed a decisive "Great Rotation" as investors abandoned high-growth technology names in...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Performance
YTD
+8.6%
+8.6%
1 Month
-4.8%
-4.8%
3 Month
+15.3%
+15.3%
6 Month
+42.7%
+42.7%
1 Year
+22.0%
+22.0%
More News
Read More
The Dividend Shield: How Meta, Microsoft, Merck, and Target are Signal-Boosting Balance Sheet Strength in a Cooling 2026 Economy
March 13, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Workforce
1 Unpopular Stock That Deserves Some Love and 2 We Avoid
March 13, 2026
Via
StockStory
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
March 10, 2026
Via
MarketMinute
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
March 10, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Lawsuit
2 Dow Jones Stocks to Research Further and 1 Facing Headwinds
March 09, 2026
Via
StockStory
Topics
Stocks
1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid
↗
March 08, 2026
Via
The Motley Fool
Topics
Intellectual Property
3 Undervalued Names Too Cheap to Ignore
↗
March 07, 2026
Via
MarketBeat
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
March 06, 2026
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies
↗
March 05, 2026
Via
The Motley Fool
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era
March 05, 2026
Via
Finterra
Topics
Intellectual Property
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
March 04, 2026
Via
MarketMinute
Topics
Earnings
Economy
2 High-Flying Stocks With More Upside to Buy and Hold
↗
March 04, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Supply Chain
IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions
↗
March 03, 2026
Via
Stocktwits
Topics
Earnings
Supply Chain
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook
↗
March 03, 2026
Via
Stocktwits
Topics
Artificial Intelligence
USDA Deploys $100 Million 'Screwworm Challenge' to Safeguard U.S. Livestock and Dairy Frontier
March 02, 2026
Via
MarketMinute
Topics
Economy
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend
↗
March 02, 2026
Via
Stocktwits
Topics
Artificial Intelligence
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
February 28, 2026
From
Merck & Co., Inc
Via
Business Wire
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
February 28, 2026
From
Merck & Co., Inc.
Via
Business Wire
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade
↗
February 28, 2026
Via
The Motley Fool
Topics
Lawsuit
Big Tech’s Heavy Lifting: S&P 500 Q4 Earnings Surpass 8% Growth Amid AI Capex Anxiety
February 27, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Electric Vehicles
What's going on in today's session: S&P500 movers
↗
February 27, 2026
Via
Chartmill
Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag
February 27, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
February 27, 2026
From
Merck & Co., Inc.
Via
Business Wire
Frequently Asked Questions
Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 115.61
When was Merck & Co last traded?
The last trade of Merck & Co was at 03/13/26 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 292.65B
How many shares of Merck & Co are outstanding?
Merck & Co has 293B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.